Contents

Search

imetelstat (Rytelo)

Indications: - relapsed or refractory low- to intermediate-risk myelodysplastic syndrome with transfusion-dependent anemia requiring >= 4 RBC units over 8 weeks & not or no longer candidates for erythropoiesis-stimulating agents Dosage: - 7.1 mg/kg administered as IV infusion over 2 hours every 28 days Adverse effects: - >= 10% - thrombocytopenia, leukopenia, neutropenia, prolonged PTT - elevated serum ALT, serum AST, serum alkaline phosphatase - fatigue, arthralgia/myalgia, COVID-19, headache Mechanism of action: - oligonucleotide telomerase inhibitor - provides transfusion independence (up to 1 year) - disease-modifying activity for heavily transfused patients [2]

General

antineoplastic agent (chemotherapeutic agent)

Database Correlations

PUBCHEM cid=72941969

References

  1. Worcester S FDA Approves Imetelstat for Lower-Risk Myelodysplastic Syndromes. Medscape. June 7, 2024 https://www.medscape.com/viewarticle/fda-approves-imetelstat-lower-risk-myelodysplastic-syndromes-2024a1000as3
  2. Platzbecker U, Santini V, Fenaux P et al Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024 Jan 20;403(10423):249-260. PMID: 38048786 Clinical Trial.